Update of the Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis

作者: Jesús Tornero Molina , Raimon Sanmartí Sala , Vicente Rodríguez Valverde , Emilio Martín Mola , José Luis Marenco de la Fuente

DOI: 10.1016/S2173-5743(10)70006-X

关键词: Systematic reviewMedicineDiseaseEvidence-based medicineDelphi methodInternal medicineAlternative medicinePhysical therapyBiologic therapiesRheumatologyIntensive care medicineRheumatoid arthritis

摘要: Abstract Objective To provide a reference to rheumatologists and those involved in the treatment of RA who are using, or about use biologic therapy. Methods Recommendations were developed following nominal group methodology based on systematic reviews. The level evidence grade recommendation classified according model proposed by Center for Evidence Based Medicine at Oxford. agreement was established through Delphi technique. Results We have produced recommendations seven agents available our country. objective is achieve remission disease as quickly possible. Indications nuances regarding therapy reviewed well evaluation that should be performed prior administration follow up patients undergoing this Conclusions present an update SER with RA.

参考文章(108)
J Sibilia, Rene Westhovens, Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology. ,vol. 25, ,(2007)
van Riel Pl, van 't Hof M, van de Putte Lb, van der Heijde Dm, Development of a disease activity score based on judgment in clinical practice by rheumatologists The Journal of Rheumatology. ,vol. 20, pp. 579- 581 ,(1993)
Bernard Burnand, Steven J. Bernstein, Kathryn Fitch, Marfa D. Aguilar, Juan R. LaCalle, The Rand/UCLA Appropriateness Method User's Manual ,(2001)
Edward C Keystone, Safety of biologic therapies--an update. The Journal of Rheumatology Supplement. ,vol. 74, pp. 8- 12 ,(2005)
Bernhard Rintelen, Burkhard F Leeb, Adil Maktari, Thomas Nothnagl, Pia M Haindl, Disease activity score-28 values differ considerably depending on patient's pain perception and sex. The Journal of Rheumatology. ,vol. 34, pp. 2382- 2387 ,(2007)
Lamiae Bensouda-Grimaldi, Denis Mulleman, Jean-Pierre Valat, Elisabeth Autret-Leca, Adalimumab-associated multiple sclerosis. The Journal of Rheumatology. ,vol. 34, pp. 239- 240 ,(2007)
P.L.C.M. van Riel, P. Emery, C. Antoni, J.R. Kalden, J.M. Alvaro-Gracia, C.V. Strand, J.M.J. Kremer, J.S. Smolen, B. Combe, Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis. The Journal of Rheumatology. ,vol. 32, pp. 1620- 1631 ,(2005)
Charles A Birbara, Vibeke Strand, Daniel E Furst, Michael H Schiff, Roy M Fleischmann, Daniele Compagnone, Steven A Fischkoff, Elliot K Chartash, Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). The Journal of Rheumatology. ,vol. 30, pp. 2563- 2571 ,(2003)
Charles Birbara, Alan J Kivitz, Allison Y Luo, Jeffrey L Kaine, Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. The Journal of Rheumatology. ,vol. 34, pp. 272- 279 ,(2007)